Delaware’s top court ruled in GSK’s favor in saying it will review the admissibility of expert evidence in an upcoming trial ...

(Reuters) - GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness ...

GSK has won its latest trial over whether its former best-selling ... known as NDMA that had been found in GSK’s heartburn ...

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.

Twelve days after GSK secured a key win in Florida ... to take to early trials. On the first track, plaintiffs have retained 10 experts to offer their opinions on whether ranitidine can cause ...

GSK plc (LSE/NYSE: GSK), a leading global pharmaceutical company, has reached a confidential settlement in a Zantac (ranitidine ... SWIFT-2 phase III clinical trials. However, the company ...

London: British pharmaceutical group GSK on Friday welcomed victory in drawn out US litigation regarding its Zantac drug for heartburn that allegedly caused cancer. The over-the-counter treatment ...

Plaintiffs in the case have argued that ranitidine can cause cancer. The drug was marketed for years by GSK (GSK) under the brand name Zantac and by various generic drugmakers. GSK (GSK ...

Investing.com -- Shares of GSK ... trial. At 4:31 am (0831 GMT), GSK was trading 1.5% higher at £1,642.11. The litigation at the center of this legal battle revolves around allegations that ...

Zamboni is expected to say the 'Tanner study - which was not submitted to the FDA until 2019 - provides evidence that GSK knew about Zantac's potential health impacts, but failed to make the ...

GSK plc (LSE/NYSE: LON:GSK), a leading global pharmaceutical company, has reached a confidential settlement in a Zantac (ranitidine ... in its SWIFT-1 and SWIFT-2 phase III clinical trials. However, ...